Genomic Classifier in Prostate Cancer: High-Risk VL

The Future of Prostate Cancer Risk Stratification and Treatment Planning - Eric Kim

Details
Preston Sprenkle and Eric Kim discuss the future of prostate cancer diagnostics, emphasizing the role of genomic classifiers like PAM50 and MRI in refining patient treatment plans. Dr. Kim suggests that prostate cancer care may soon parallel advances in breast cancer, utilizing gene pathway analyses to guide treatment decisions more accurately. They explore how integrating complex biomarkers into...

The Future of Prostate Cancer Diagnosis: Combining Non-Invasive Tests for Personalized Care - Eric Kim

Details
Preston Sprenkle discusses with Eric Kim the integration of MRI and genomic classifiers in prostate cancer management. They explore the potential of artificial intelligence (AI) to enhance diagnostic accuracy and personalization of treatment. Dr. Kim reflects on his project, which investigates correlations between MRI findings and genomic data from a large cohort, noting the challenges of consiste...

Investigating the Relationship Between MRI Findings, Genomic Markers, and Gleason Score - Eric Kim

Details
Eric Kim discusses the variation in prostate cancer genomic subtypes related to MRI PI-RADS scores and racial differences. He focused on the correlations between mpMRI findings and the Decipher genomic classifier in a racially diverse cohort of men. The study revealed that MRI and Decipher scores generally correlated well, especially in non-African Americans, but this correlation was weaker among...

Decipher Scores and PSMA PET Imaging: A Correlative Study in High-Risk Prostate Cancer - Amar Kishan

Details
Daniel Spratt engages with Amar Kishan about the role of transcriptomic profiling and PSMA PET imaging in prostate cancer. Dr. Kishan discusses a study involving 18 trials and 12,500 patients, which suggests that extra-prostatic disease is often the driver of distant metastasis in high-risk patients. The study also explores the correlation between Decipher scores and the risk of upstaging on PSMA...

Insights from the STAMPEDE Trial Platform - Marina Parry & Gerhardt Attard

Details
Marina Parry and Gerhardt Attard join Alicia Morgans in discussing two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for metastatic hormone-sensitive prostate cancer (mHSPC) starting ADT: overall survival (OS) results of 2 randomized Phase III trials from the STAMPEDE pr...

Adjuvant Treatment for Men with Prostate Cancer with High Risk of Metastasis, the ERADICATE Study - Ashley Ross

Details
In this discussion, Alicia Morgans and Ashley Ross discuss men in the adjuvant setting with the highest risk of prostate cancer metastasis by genomic stratification. They focus their discussion on Decipher molecular testing after prostatectomy and the Phase III ERADICATE study. The ERADICATE trial was presented at this year's ASCO meeting. Biographies: Ashley Ross, MD, Ph.D., Associate Professor,...

Decipher Biopsy and Decipher for Prostatectomy in Clinical Practice- Ashley Ross

Details
Alicia Morgans and Ashley Ross discuss Decipher testing, both Decipher Biopsy and Decipher for prostatectomy specimens, and how to integrate these tests into standard clinical practice. Decipher is a genomic classifier that looks at the whole genome and expression patterns on that genome. The genomic classifier score is a prognostic score that goes from 0 to 1, and it was first developed to strati...

The Benefit of ADT Treatment Intensification With Radiotherapy in Localized Prostate Cancer – Dan Spratt and Amar Kishan

Details
Daniel Spratt and Amar Kishan discuss a Lancet Oncology publication, on behalf of the MARCAP Consortium, titled "Androgen Deprivation Therapy Use and Duration with Definitive Radiotherapy for Localised Prostate Cancer: An Individual Patient Data Meta-Analysis." Led by Dr. Kishan, this individual patient data meta-analysis of relevant randomized trials aimed to quantify the benefit of various andro...

The Conundrum of Systemic Salvage Therapy at the Time of Salvage Radiation Therapy - Brandon Mahal

Details
Alicia Morgans sits down with Brandon Mahal to explore the complexities of using salvage systemic therapy alongside salvage radiation therapy for post-prostatectomy patients. Dr. Mahal outlines the current conundrum: whether to administer Androgen Deprivation Therapy (ADT) and for how long, especially for men with high PSAs post-surgery. He references multiple randomized trials that offer conflict...

The Performance of a Genomic Classifier Score in the Phase 3 SAKK 09/10 in Patients with Biochemical Progression - Alan Dal Pra

Details
Alan Dal Pra joins Alicia Morgans in a discussion on the SAKK 09/10 trial presented at the 2021 ASTRO meeting. Dr. Alan Dal Pra highlights the efficacy of very intensive versus less intensive radiation in the biochemical recurrent prostate cancer population. This conversation also touches on Decipher® scores and PSA values in these patients. Biographies: Alan Dal Pra, MD, Assistant Professor and A...